Phase III nasal polyps data for Dupixent presented at AAAAI

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) presented detailed data at the American Academy of Allergy, Asthma & Immunology meeting from a pair of Phase III trials evaluating Dupixent dupilumab to treat recurring severe chronic rhinosinusitis with nasal polyps.

In October, the partners reported that 300 mg Dupixent every two weeks met the co-primary endpoints of improving nasal congestion/obstruction severity and nasal polyps score from baseline to week 24 vs. placebo in both the Phase III SINUS-24 and SINUS-52 trials (p<0.0001 for all)...